These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36838749)

  • 1. Structure-Based Virtual Screening and Molecular Dynamics Simulation Assessments of Depsidones as Possible Selective Cannabinoid Receptor Type 2 Agonists.
    Mohamed GA; Omar AM; AlKharboush DF; Fallatah MA; Sindi IA; El-Agamy DS; Ibrahim SRM
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docking and Molecular Dynamic Investigations of Phenylspirodrimanes as Cannabinoid Receptor-2 Agonists.
    Omar AM; Aljahdali AS; Safo MK; Mohamed GA; Ibrahim SRM
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of the Binding Affinities and Selectivity for CB1 and CB2 Ligands Using Homology Modeling, Molecular Docking, Molecular Dynamics Simulations, and MM-PBSA Binding Free Energy Calculations.
    Ji B; Liu S; He X; Man VH; Xie XQ; Wang J
    ACS Chem Neurosci; 2020 Apr; 11(8):1139-1158. PubMed ID: 32196303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB
    Aviz-Amador A; Contreras-Puentes N; Mercado-Camargo J
    Comput Biol Chem; 2021 Dec; 95():107590. PubMed ID: 34700256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
    Pandey P; Roy KK; Doerksen RJ
    J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands.
    Yang JF; Williams AH; Penthala NR; Prather PL; Crooks PA; Zhan CG
    ACS Chem Neurosci; 2020 Oct; 11(20):3455-3463. PubMed ID: 32997485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G
    Hua T; Li X; Wu L; Iliopoulos-Tsoutsouvas C; Wang Y; Wu M; Shen L; Brust CA; Nikas SP; Song F; Song X; Yuan S; Sun Q; Wu Y; Jiang S; Grim TW; Benchama O; Stahl EL; Zvonok N; Zhao S; Bohn LM; Makriyannis A; Liu ZJ
    Cell; 2020 Feb; 180(4):655-665.e18. PubMed ID: 32004463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
    Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
    Floresta G; Apirakkan O; Rescifina A; Abbate V
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation of partial activation of cannabinoid receptor type 2 and identification of potential partial agonists: Molecular dynamics simulation and structure-based virtual screening.
    Uba AI; Aluwala H; Liu H; Wu C
    Comput Biol Chem; 2022 Aug; 99():107723. PubMed ID: 35850049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
    Penthala NR; Shoeib A; Dachavaram SS; Cabanlong CV; Yang J; Zhan CG; Prather PL; Crooks PA
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127501. PubMed ID: 32882418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the 1,3-benzoxazine chemotype for cannabinoid receptor 2 as a promising anti-cancer therapeutic.
    Gambacorta N; Gasperi V; Guzzo T; Di Leva FS; Ciriaco F; Sánchez C; Tullio V; Rozzi D; Marinelli L; Topai A; Nicolotti O; Maccarrone M
    Eur J Med Chem; 2023 Nov; 259():115647. PubMed ID: 37478557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2.
    Liu C; Yuan C; Wu P; Zhu C; Fang H; Wang L; Fu W
    Chem Biol Drug Des; 2018 Sep; 92(3):1699-1707. PubMed ID: 29797785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal Structure of the Human Cannabinoid Receptor CB2.
    Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
    Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of the CB
    Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
    BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies.
    Chen JJ; Han S; Cao Y; Chen JZ
    Yao Xue Xue Bao; 2013 Sep; 48(9):1436-49. PubMed ID: 24358778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel CB2 Ligands through Virtual Screening and In Vitro Evaluation.
    Stasiulewicz A; Lesniak A; Bujalska-Zadrożny M; Pawiński T; Sulkowska JI
    J Chem Inf Model; 2023 Feb; 63(3):1012-1027. PubMed ID: 36693026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β 2 AR.
    Latek D; Kolinski M; Ghoshdastider U; Debinski A; Bombolewski R; Plazinska A; Jozwiak K; Filipek S
    J Mol Model; 2011 Sep; 17(9):2353-66. PubMed ID: 21365223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists.
    Cascio MG; Bolognini D; Pertwee RG; Palazzo E; Corelli F; Pasquini S; Di Marzo V; Maione S
    Pharmacol Res; 2010 Apr; 61(4):349-54. PubMed ID: 19961936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.